Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Personalized Diagnosis, Treatment, and Prognosis of Parkinson’s Disease
share announcement

Personalized Diagnosis, Treatment, and Prognosis of Parkinson’s Disease

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 5387

Special Issue Editors

Dr. Cheng-Hsien Lu

E-Mail Website
Guest Editor
Department of Neurology, Chang Gung Memorial Hospital-Kaohsiung and Chang Gung University, 123, Ta-Pei Road, Niao Sung district, Kaohsiung City 83304, Taiwan
Interests: neuroscience; Parkinson’s disease; diabetic peripheral neuropathy; central nervous system infection
Dr. Wei-Che Lin

E-Mail Website
Guest Editor
Department of Diagnostic Radiology, Chang Gung Memorial Hospital-Kaohsiung and Chang Gung University, 123, Ta-Pei Road, Niao Sung District, Kaohsiung City 83304, Taiwan
Interests: head and neck radiology; MRI post-processing; percutaneous vertebroplasty; interventional radiology

Special Issue Information

Dear Colleagues,

Although effective treatments for the symptom control of Parkinson's disease (PD) have been developed in the past 20 years, it remains a clinical diagnosis based on motor and nonmotor signs and symptoms. Our understanding of the pathophysiology, phenotypic diversity, and progression of Parkinson's disease remains unsatisfactory.

This Special Issue “Personalized Diagnosis, Treatment, and Prognosis of Parkinson’s Disease” aims to highlight the current state of science and showcase some of the latest findings in the field of PD.

We invite researchers in this field to submit original research and review articles, including studies on the discovery of novel biomarkers and new targets for therapeutic interventions to pave the path towards developing personalized medicine to achieve optimal health and wellness in PD.

Dr. Cheng-Hsien Lu
Dr. Wei-Che Lin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • diagnosis
  • pthophysiology
  • prognosis
  • outcome
  • treatment

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1890 KiB  
Article
Association between Statin Use and Risk of Parkinson’s Disease: Evidence from 18 Observational Studies Comprising 3.7 Million Individuals
by Chieh-Chen Wu, Md. Mohaimenul Islam, An-Jen Lee, Chun-Hsien Su, Yung-Ching Weng, Chih-Yang Yeh, Hsun-Hua Lee and Ming-Chin Lin
J. Pers. Med. 2022, 12(5), 825; https://doi.org/10.3390/jpm12050825 - 19 May 2022
Cited by 7 | Viewed by 3015
Abstract
The potential impact of statins on the risk of Parkinson’s disease (PD) is still controversial; therefore, we conducted a comprehensive meta-analysis of observational studies to examine the effect of statin use on the risk of PD. We searched electronic databases, such as PubMed, [...] Read more.
The potential impact of statins on the risk of Parkinson’s disease (PD) is still controversial; therefore, we conducted a comprehensive meta-analysis of observational studies to examine the effect of statin use on the risk of PD. We searched electronic databases, such as PubMed, EMBASE, Scopus, and Web of Science, for articles published between 1 January 2000 and 15 March 2022. Cohort studies which examined the association between statins and PD risk in the general population were also included. Two authors assessed the data and extracted all potential information for analysis. Random effects meta-analyses were performed to measure the risk ratio (RR) and 95% confidence intervals (CIs). Eighteen cohort studies including 3.7 million individuals with 31,153 PD participants were identified. In statin users, compared with non-users, the RR for PD was 0.79 (95% CI: 0.68–0.91). In a subgroup analysis of PD, this association was observed with medium and high quality, and the studies were adjusted for age, gender, and smoking status. When the data were stratified according to the duration of exposure, long-duration statin use was associated with a decreased risk of PD (RR = 0.49; 95% CI: 0.26–0.92). There was no significant decrease in the risk of PD in short-term statin users (RR = 0.94; 95% CI: 0.67–1.31). Moreover, no significant difference in the reduction in the risk of PD was observed between men (RR = 0.80; 95% CI: 0.75–0.86) and women (RR = 0.80; 95% CI: 0.75–0.86). Although our findings confirm a reduction in the PD risk associated with statin treatment and suggest that statins play a clinically favorable role, these findings should be interpreted with caution. Future randomized control trials with an ad hoc design are needed to confirm the potential utility of statins in reducing the risk of PD. Full article
(This article belongs to the Special Issue Personalized Diagnosis, Treatment, and Prognosis of Parkinson’s Disease)
►▼ Show Figures

Figure 1

13 pages, 511 KiB  
Article
Dysosmia Is a Predictor of Motor Function and Quality of Life in Patients with Parkinson’s Disease
by Chia-Yen Lin, Ting-Ya Chang and Ming-Hong Chang
J. Pers. Med. 2022, 12(5), 754; https://doi.org/10.3390/jpm12050754 - 6 May 2022
Cited by 2 | Viewed by 1835
Abstract
(1) Background: The correlation between dysosmia with quality of life (QoL) in patients with PD was rarely reported. The study aimed to examine the effect of dysosmia on motor function and QoL in PD. (2) Methods: This cross-sectional study, performed between October 2016 [...] Read more.
(1) Background: The correlation between dysosmia with quality of life (QoL) in patients with PD was rarely reported. The study aimed to examine the effect of dysosmia on motor function and QoL in PD. (2) Methods: This cross-sectional study, performed between October 2016 and February 2021, recorded the traditional Chinese version of the University of Pennsylvania Smell Identification Test (UPSIT), the Montreal Cognitive Assessment (MoCA), the Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS UPDRS), and the 39-item Parkinson’s Disease Questionnaire (PDQ-39) in patients with PD. UPSIT = 19 was applied to separate the total anosmia and non-anosmia groups. (3) Results: 243 patients with PD were recruited. The total anosmia group had higher MDS UPDRS total, part II, and part III scores than the non-anosmia group. They also had worse scores on the dimensions of activities of daily living (ADL) and cognition of the PDQ-39 than the non-anosmia group. The UPSIT score correlated MDS UPDRS part III score (p < 0.0001), PDQ-39 ADL quartile (p = 0.0202), and Dopamine transporter scan (p = 0.0082) in the linear regression. (4) Conclusions: Dysosmia in PD predicted a phenotype with defective motor function, ADL, and cognition QoL. The findings supported the olfactory transmission of α-synuclein to the cortices, substantia nigra. Full article
(This article belongs to the Special Issue Personalized Diagnosis, Treatment, and Prognosis of Parkinson’s Disease)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop